The Latest Breaking News from Raymond James

Upgrades

Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00. Shares of Galmed Pharmaceuticals are trading down 22.69% over the last 24 hours, at $0.94 per share.

Upgrades

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance. 

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses.  The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table.  HIV sales,…

Apple Inc (NASDAQ: AAPL) reported better-than-expected second-quarter earnings and revenues.

Shares of PayPal Holdings Inc (NASDAQ: PYPL) gained 11% on Thursday after the company reported a revenue beat but cut its 2022 guidance.

Shares of social media and metaverse company Meta Platforms Inc (NASDAQ: FB) traded higher Wednesday after market close. The move came after the company reported first-quarter financial results. Here are the key takeaways from the earnings report from analysts.

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…